PT  - JOURNAL ARTICLE
AU  - Henry, L. Keith
AU  - Blakely, Randy D.
TI  - Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend
AID  - 10.1124/mol.107.044586
DP  - 2008 Mar 01
TA  - Molecular Pharmacology
PG  - 616--618
VI  - 73
IP  - 3
4099  - http://molpharm.aspetjournals.org/content/73/3/616.short
4100  - http://molpharm.aspetjournals.org/content/73/3/616.full
SO  - Mol Pharmacol2008 Mar 01; 73
AB  - Abuse of psychostimulants such as cocaine and amphetamines has a tremendous social and economic impact. Although replacement therapies are offered for addiction to opioids, nicotine, and alcohol, there is no approved replacement treatment for psychostimulant addiction. Recent studies on an emerging group of benztropine- and rimcazole-based compounds provide hope that replacement therapies for cocaine and amphetamine addiction may come in the near future. A new study (p. 813) now investigates the molecular interaction of the benztropine and rimcazole compounds with their target, the dopamine transporter, and provides an intriguing explanation as to why use of these compounds, unlike cocaine, do not lead to locomotor stimulation and drug discrimination behaviors in animal models. The American Society for Pharmacology and Experimental Therapeutics